| Population 2015 |
11 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
2.7 |
(1.6–4) |
24 |
(14–36) |
| Mortality (HIV+TB only) |
0.66 |
(0.32–1.1) |
5.9 |
(2.9–10) |
| Incidence (includes HIV+TB) |
14 |
(8.8–19) |
122 |
(79–174) |
| Incidence (HIV+TB only) |
1.9 |
(1.2–2.7) |
17 |
(11–24) |
| Incidence (MDR/RR-TB)** |
0.5 |
(0.21–0.8) |
4.5 |
(1.9–7.2) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
0.75 |
(0.25–1.2) |
4.1 |
(1.4–6.9) |
4.9 |
(1.7–8.1) |
| Males |
0.97 |
(0.58–1.4) |
7.8 |
(5.3–10) |
8.8 |
(5.9–12) |
| Total |
1.7 |
(1.1–2.3) |
12 |
(8.9–15) |
14 |
(8.8–19) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
6 969 |
| Total new and relapse |
6 892 |
| - % tested with rapid diagnostics at time of diagnosis |
8% |
| - % with known HIV status |
95% |
| - % pulmonary |
70% |
| - % bacteriologically confirmed among pulmonary |
88% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
51% (35–78) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.25 (0.14–0.43) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
907 |
14% |
| - on antiretroviral therapy |
851 |
94% |
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
190
(100–270) |
| Estimated % of TB cases with MDR/RR-TB |
3.2% (1.4–5) |
14% (6.9–21) |
|
| % notified tested for rifampicin resistance |
9% |
0% |
584 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
0 |
| Laboratory-confirmed cases |
MDR/RR-TB: 44, XDR-TB: 0 |
| Patients started on treatment **** |
MDR/RR-TB: 41, XDR-TB: 0 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
91% |
7 309 |
| Previously treated cases, excluding relapse, registered in 2014 |
82% |
83 |
| HIV-positive TB cases, all types, registered in 2014 |
86% |
901 |
| MDR/RR-TB cases started on second-line treatment in 2013 |
89% |
38 |
| XDR-TB cases started on second-line treatment in 2013 |
|
0 |
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
18% (17–20) |
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
|
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |